UBA1 and cancer: Since aberrant protein ubiquitylation is typically found in the cancer cell and the E1-activating step is almost exclusively catalysed by UBA1, novel small molecule compounds are continuously developed against this protein, further expanding future therapeutic possibilities [21, 52].